JPMorgan Chase Analysts Give AstraZeneca (AZN) a GBX 5,500 Price Target
AZN has been the subject of several other research reports. Jefferies Group upgraded shares of AstraZeneca from a hold rating to a buy rating and upped their price target for the stock from GBX 5,075 ($72.67) to GBX 5,600 ($80.18) in a research report on Monday, March 19th. UBS set a GBX 4,550 ($65.15) target price on shares of AstraZeneca and gave the company a neutral rating in a research report on Monday, January 8th. Liberum Capital reiterated a hold rating and issued a GBX 5,000 ($71.59) target price on shares of AstraZeneca in a research report on Friday, January 26th. Shore Capital reiterated a hold rating on shares of AstraZeneca in a research report on Monday, March 5th. Finally, Barclays reiterated an overweight rating and issued a GBX 6,300 ($90.21) target price on shares of AstraZeneca in a research report on Monday, December 18th. Four analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. AstraZeneca has a consensus rating of Hold and a consensus target price of GBX 5,226.87 ($74.84).
AstraZeneca stock opened at GBX 4,915.50 ($70.38) on Friday. AstraZeneca has a one year low of GBX 4,260 ($61.00) and a one year high of GBX 5,520 ($79.04).
In other AstraZeneca news, insider Philip A. J. Broadley acquired 415 shares of AstraZeneca stock in a transaction dated Friday, February 2nd. The stock was bought at an average price of GBX 4,846 ($69.39) per share, for a total transaction of £20,110.90 ($28,795.68).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.